BTIG Reiterates Hold Rating on Vicarious Surgical (RBOT)

BTIG analyst Ryan Zimmerman reiterated a Hold rating on Vicarious Surgical (RBOT) in a report released yesterday. Zimmerman has an average return of -2.6% and a 39.23% success rate. The stock has a Moderate Buy analyst consensus rating with a $13.00 average price target. RBOT's market cap is $61.4M and has a P/E ratio of -0.99. There has been an increase in insider selling in the past quarter.

Vicarious Surgical, a developer of single-port robotic systems for abdominal procedures, has announced a delay in its clinical trial for the robotic system. The company, which has large for-profit hospital operator HCA Healthcare and Bill Gates among its investors, now expects to complete the design for the commercial version of the system before proceeding with clinical trials [1].

Stephen From, who joined Vicarious as CEO in late July, stated during the company's second-quarter earnings call that the clinical trial’s timing will determine when the robot developer submits its de novo filing to the Food and Drug Administration (FDA). Vicarious had previously planned to make its FDA submission in late 2026, after delaying the start of the trial. The company is now focusing on an assessment over about four to six weeks to gauge the readiness of the system for verification [1].

From emphasized that the single-port robotic market is still in its early stages and believes Vicarious' differentiated platform and strong technical foundation will advance minimally invasive surgery. He added that the company's system is not just a copycat but deserves market share [1].

Vicarious ended the second quarter with about $24 million in cash and expects its cash burn to be about $50 million for fiscal 2025. The company will likely need to seek non-dilutive financing to maintain operations or meaningfully cut expenses, according to BTIG analyst Ryan Zimmerman [1].

Zimmerman reiterated a Hold rating on Vicarious Surgical (RBOT) in a report released yesterday. The stock has a Moderate Buy analyst consensus rating with a $13.00 average price target. RBOT's market cap is $61.4M and has a P/E ratio of -0.99. There has been an increase in insider selling in the past quarter [2].

References:
[1] https://www.medtechdive.com/news/Vicarious-Surgical-delays-robot-timeline/757636/
[2] https://www.tipranks.com/stocks/rbot/forecast